Huikuan Chu, M.D., is an Associate Professor and Associate Chief Physician at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, and a leading researcher in gastroenterology with a strong focus on intestinal microecology and digestive diseases. As Chief Scientist of the Young Scientist Project under China’s National Key Research and Development Program, she advances innovative strategies for diagnosing and treating digestive disorders through microbiota-targeted interventions. Dr. Chu has built an influential academic profile with 61 published documents, an h-index of 23, and 2,676 total citations, reflecting the global impact of her scientific contributions. Her pioneering work includes uncovering how Candida albicans and its exotoxin candidalysin exacerbate alcohol-associated liver disease, reshaping understanding of gut mycobiome involvement in hepatology and challenging long-standing gaps in conventional digestive-disease research. She has published more than 20 high-quality papers in leading international journals such as Gut, Journal of Hepatology, Nature Communications, and Translational Research. Her major funded projects span mechanistic studies of gut microbiota dysbiosis, hepatocyte injury pathways, and the development of early-screening diagnostic tools for metabolic and liver-related complications. She has delivered invited reports and plenary lectures at major international conferences, including ANMA, AASLD, EASL, and PSGR, earning notable distinctions such as the AASLD Early Career Investigator Award and Best Abstract Award. Recognized for her scientific rigor and translational mindset, Dr. Chu continues to drive forward-looking research aimed at developing targeted therapies, restoring gut–liver axis homeostasis, and improving clinical outcomes for patients affected by alcohol-associated and metabolic liver diseases.